NEW YORK Aims of becoming a leader in biotechnology headlined a meeting Thursday between Bristol-Myers Squibb and investors as the drug maker highlighted a pipeline of late-stage and early-development drugs.
Like many big drug companies, Bristol has focused on beefing up its pipeline as it faces big patent expirations over the next few years, particularly for the anti-clotting drug Plavix (clopidogrel). The company has particularly high hopes for investigative compounds to treat Alzheimer’s disease and hepatitis C.
“I am fully confident in our ability to deliver on our three major strategic imperatives – driving our performance in the next few years, improving our earnings base in 2013 and sustaining growth in 2014 and beyond,” said Bristol president and COO Lamberto Andreotti, who will soon replace James Cornelius as CEO. “We have important strategic, operational and financial levers which will allow us to fully realize our potential as a biopharma leader, and to deliver on our near-term and long-term growth opportunities.”